Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLYG8824A in locally advanced or metastatic colorectal cancer
NCT04468607Phase 1Completed
- Sponsor
- Genentech
- Start
- Aug 2020
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of linclatamig in colorectal cancer (CRC) (2 arms), sponsored by Genentech. Primary endpoints: Incidence and Nature of Dose-Limiting Toxicities, Number of Patricipants with Adverse Events and 3 more. Started Aug 2020; status: completed.
02
Drugs
linclatamig
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04468607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04468607.